Vitrolife AB (publ) (VITR.ST)
SEK 154.7
(-1.84%)
SEK 154.7
(-1.84%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 1.97 Billion SEK | -2.36% |
| 2022 | 1.78 Billion SEK | 70.16% |
| 2021 | 1.04 Billion SEK | 36.27% |
| 2020 | 767.66 Million SEK | -18.22% |
| 2019 | 938.65 Million SEK | 23.32% |
| 2018 | 761.12 Million SEK | 11.65% |
| 2017 | 681.7 Million SEK | 21.45% |
| 2016 | 561.3 Million SEK | 15.78% |
| 2015 | 484.82 Million SEK | 38.87% |
| 2014 | 349.11 Million SEK | 16.16% |
| 2013 | 300.55 Million SEK | 26.12% |
| 2012 | 238.3 Million SEK | 0.01% |
| 2011 | 238.27 Million SEK | 15.58% |
| 2010 | 206.15 Million SEK | 6.88% |
| 2009 | 192.88 Million SEK | 23.45% |
| 2008 | 156.25 Million SEK | 20.5% |
| 2007 | 129.66 Million SEK | 11.28% |
| 2006 | 116.52 Million SEK | 40.51% |
| 2005 | 82.92 Million SEK | 11.5% |
| 2004 | 74.37 Million SEK | 20.66% |
| 2003 | 61.63 Million SEK | 24.87% |
| 2002 | 49.36 Million SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 499 Million SEK | 19.38% |
| 2024 Q1 | 418 Million SEK | -7.52% |
| 2024 Q3 | 508 Million SEK | 1.8% |
| 2023 FY | 1.73 Billion SEK | -2.36% |
| 2023 Q1 | 485 Million SEK | 4.75% |
| 2023 Q2 | 505 Million SEK | 4.12% |
| 2023 Q3 | 473 Million SEK | -6.34% |
| 2023 Q4 | 452 Million SEK | -4.44% |
| 2022 Q2 | 471 Million SEK | 12.41% |
| 2022 Q1 | 419 Million SEK | 39.93% |
| 2022 Q3 | 427 Million SEK | -9.34% |
| 2022 Q4 | 463 Million SEK | 8.43% |
| 2022 FY | 1.78 Billion SEK | 70.16% |
| 2021 Q1 | 246.95 Million SEK | -1.93% |
| 2021 Q2 | 237.14 Million SEK | -3.98% |
| 2021 Q4 | 299.42 Million SEK | 14.04% |
| 2021 FY | 1.04 Billion SEK | 36.27% |
| 2021 Q3 | 262.56 Million SEK | 10.72% |
| 2020 Q4 | 251.82 Million SEK | 26.53% |
| 2020 FY | 767.66 Million SEK | -18.22% |
| 2020 Q2 | 111.19 Million SEK | -45.92% |
| 2020 Q3 | 199.02 Million SEK | 78.99% |
| 2020 Q1 | 205.62 Million SEK | -18.56% |
| 2019 Q3 | 243.34 Million SEK | -0.64% |
| 2019 Q4 | 252.48 Million SEK | 3.76% |
| 2019 Q2 | 244.9 Million SEK | 23.75% |
| 2019 FY | 938.65 Million SEK | 23.32% |
| 2019 Q1 | 197.9 Million SEK | -7.7% |
| 2018 Q4 | 214.42 Million SEK | 14.14% |
| 2018 Q2 | 187.33 Million SEK | 9.23% |
| 2018 Q3 | 187.85 Million SEK | 0.28% |
| 2018 Q1 | 171.5 Million SEK | -1.41% |
| 2018 FY | 761.12 Million SEK | 11.65% |
| 2017 Q4 | 173.96 Million SEK | 6.5% |
| 2017 FY | 681.7 Million SEK | 21.45% |
| 2017 Q2 | 186.61 Million SEK | 18.26% |
| 2017 Q1 | 157.79 Million SEK | -6.34% |
| 2017 Q3 | 163.34 Million SEK | -12.47% |
| 2016 Q3 | 130.91 Million SEK | -4.25% |
| 2016 FY | 561.3 Million SEK | 15.78% |
| 2016 Q1 | 125.17 Million SEK | -8.57% |
| 2016 Q2 | 136.72 Million SEK | 9.23% |
| 2016 Q4 | 168.48 Million SEK | 28.69% |
| 2015 FY | 484.82 Million SEK | 38.87% |
| 2015 Q4 | 136.91 Million SEK | 14.44% |
| 2015 Q1 | 106.43 Million SEK | 17.91% |
| 2015 Q2 | 121.83 Million SEK | 14.47% |
| 2015 Q3 | 119.63 Million SEK | -1.81% |
| 2014 Q2 | 89.04 Million SEK | 10.04% |
| 2014 Q1 | 80.92 Million SEK | -2.92% |
| 2014 FY | 349.11 Million SEK | 16.16% |
| 2014 Q4 | 90.26 Million SEK | 1.56% |
| 2014 Q3 | 88.87 Million SEK | -0.19% |
| 2013 FY | 300.55 Million SEK | 26.12% |
| 2013 Q2 | 76.13 Million SEK | 10.96% |
| 2013 Q1 | 68.61 Million SEK | 8.12% |
| 2013 Q3 | 72.44 Million SEK | -4.85% |
| 2013 Q4 | 83.35 Million SEK | 15.06% |
| 2012 FY | 238.3 Million SEK | 0.01% |
| 2012 Q3 | 54.93 Million SEK | -12.78% |
| 2012 Q4 | 63.46 Million SEK | 15.51% |
| 2012 Q1 | 67.89 Million SEK | 5.54% |
| 2012 Q2 | 62.98 Million SEK | -7.23% |
| 2011 Q1 | 58.8 Million SEK | 7.46% |
| 2011 FY | 238.27 Million SEK | 15.58% |
| 2011 Q4 | 64.33 Million SEK | 11.48% |
| 2011 Q3 | 57.7 Million SEK | 0.48% |
| 2011 Q2 | 57.43 Million SEK | -2.33% |
| 2010 Q1 | 51.79 Million SEK | 9.85% |
| 2010 Q2 | 51.97 Million SEK | 0.35% |
| 2010 Q3 | 47.65 Million SEK | -8.32% |
| 2010 Q4 | 54.72 Million SEK | 14.83% |
| 2010 FY | 206.15 Million SEK | 6.88% |
| 2009 FY | 192.88 Million SEK | 23.45% |
| 2009 Q2 | 50.03 Million SEK | 0.0% |
| 2009 Q4 | 47.15 Million SEK | 1.42% |
| 2009 Q3 | 46.49 Million SEK | -7.08% |
| 2008 FY | 156.25 Million SEK | 20.5% |
| 2007 FY | 129.66 Million SEK | 11.28% |
| 2006 FY | 116.52 Million SEK | 40.51% |
| 2005 FY | 82.92 Million SEK | 11.5% |
| 2004 FY | 74.37 Million SEK | 20.66% |
| 2003 FY | 61.63 Million SEK | 24.87% |
| 2002 FY | 49.36 Million SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Acarix AB (publ) | 5.29 Million SEK | -37241.892% |
| ADDvise Group AB (publ) | 300.6 Million SEK | -558.017% |
| ADDvise Group AB (publ) | 300.6 Million SEK | -558.017% |
| Arcoma AB | 11.07 Million SEK | -17766.498% |
| Bactiguard Holding AB (publ) | 139.98 Million SEK | -1313.049% |
| BICO Group AB (publ) | 1.83 Billion SEK | -8.052% |
| Boule Diagnostics AB (publ) | 249.71 Million SEK | -692.106% |
| CellaVision AB (publ) | 463.04 Million SEK | -327.176% |
| Clinical Laserthermia Systems AB (publ) | 2.99 Million SEK | -65899.333% |
| Chordate Medical Holding AB (publ) | -28.41 Million SEK | 7061.337% |
| C-Rad AB (publ) | 66.01 Million SEK | -2896.289% |
| Duearity AB (publ) | -4.17 Million SEK | 47443.226% |
| Dignitana AB (publ) | 58.97 Million SEK | -3254.191% |
| Episurf Medical AB (publ) | -41.8 Million SEK | 4832.057% |
| Getinge AB (publ) | 13.43 Billion SEK | 85.273% |
| Scandinavian Real Heart AB (Publ) | -50.21 Million SEK | 4038.88% |
| Iconovo AB (publ) | 17.57 Million SEK | -11152.924% |
| Integrum AB (publ) | 690.56 Thousand SEK | -286333.369% |
| Luxbright AB (publ) | -2.79 Million SEK | 70821.762% |
| Mentice AB (publ) | 236.38 Million SEK | -736.785% |
| OssDsign AB (publ) | 83.64 Million SEK | -2264.756% |
| Paxman AB (publ) | 12.61 Million SEK | -15576.018% |
| Promimic AB (publ) | 38.51 Million SEK | -5035.661% |
| Qlife Holding AB (publ) | -50.75 Million SEK | 3997.307% |
| SciBase Holding AB (publ) | 16.03 Million SEK | -12233.978% |
| ScandiDos AB (publ) | 47.55 Million SEK | -4059.394% |
| Sectra AB (publ) | 557.55 Million SEK | -254.764% |
| Sedana Medical AB (publ) | 108.98 Million SEK | -1714.995% |
| Senzime AB (publ) | 8.33 Million SEK | -23619.87% |
| SpectraCure AB (publ) | -9.22 Million SEK | 21546.384% |
| Stille AB | 132.17 Million SEK | -1396.546% |
| Xvivo Perfusion AB (publ) | 416.91 Million SEK | -374.44% |